Biomerica, Inc. BMRA 深 滬
等待開盤 10-23 09:30:00 美东时间
2.93
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 2.93
- 總市值 745.92万
- 52周最高 10.16
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 2.08
- 委 比 0.00%
- 總股本 254.58万
- 歷史最高 187.12
- 量 比 0
- 振 幅 0.00%
- 歷史最低 1.932
- 每 手 1
- 風險率 1.07%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Biomerica Enters Marketing Partnership With Henry Schein To Promote Biomerica's Infoods Irritable Bowel Syndrome Test Across The United States, Excluding New York State
Biomerica, Inc. (NASDAQ:BMRA), a global biomedical company, announced today a marketing services arrangement with Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based
10-16 20:22
Henry Schein and Biomerica Enter into Marketing Services Agreement for Biomerica’s inFoods® IBS Test in the U.S.
Biomerica partners with Henry Schein to expand marketing of its inFoods® IBS test, leveraging Henry Schein's national distribution network. The collaboration aims to accelerate adoption of Biomerica's non-drug, precision-based diagnostic therapy for IBS patients. Recent clinical studies published in *Gastroenterology* show the test significantly reduces symptoms, particularly in underserved IBS-M patients. Henry Schein's expertise and reach will ...
10-16 12:19
Biomerica Reports First Quarter Fiscal 2026 Financial Results
Biomerica reported Q1 FY2026 financial results with net sales of $1.4 million, a decrease compared to $1.8 million in Q1 FY2025, due to reduced retail activity and international order timing. Despite lower sales, gross margin improved to 31% from 16% due to higher-margin product mix. Operating expenses declined to $1.5 million from $1.7 million, reflecting cost reduction efforts. The company achieved a net profit of approximately $2,000, compared...
10-15 13:27
Biomerica Q1 Sales $1.380M Down From $1.807M YoY
Biomerica (NASDAQ:BMRA) reported $1.380 million in sales this quarter. This is a 23.63 percent decrease over sales of $1.807 million the same period last year.
10-15 06:01
Biomerica Launches AI-Backed inFoods® IBS Trigger Food Navigator to Support Personalized IBS Therapy and Improve Patient Outcomes
Biomerica launched the inFoods® IBS Trigger Food Navigator, an AI-powered tool to help IBS patients manage symptoms and avoid trigger foods identified by the inFoods® IBS test. With more than 40 million adults in the U.S. affected by IBS, the tool offers personalized meal suggestions, ingredient substitutions, and simplified meal planning. It has shown significant clinical benefits, including a 59.6% reduction in abdominal pain compared to tradit...
09-09 12:08
Biomerica shares are trading higher after the UAE Ministry of Health and Prevention approved the company's Fortel Kidney Test for home use.
Biomerica shares are trading higher after the UAE Ministry of Health and Preven...
09-03 20:20
Biomerica Reports Fiscal 2025 Year End Results
Biomerica reported net sales of $5.3 million in Fiscal 2025, slightly lower than FY 2024 due to global tariff uncertainties and product mix shifts. Operating expenses decreased by $1.3 million, achieving a 19% improvement in operating loss to $5.1 million. Strategic growth areas include advancing inFoods® IBS reimbursement pathways, expanding EZ Detect™ and H. pylori sales, and pursuing MENA market opportunities. Key milestones include PLA code i...
08-29 21:12
Reported Earlier: Biomerica's 10-Minute H. Pylori Home Test Approved In UAE
10-minute home test enables detection of Helicobacter pylori, a leading cause of peptic ulcers, dyspepsia, and gastric cancerH. pylori linked to approximately 80% of gastric cancer cases; classified as a Class 1
08-14 22:19
United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Ulcer Test for Home Use
Biomerica's Fortel® Ulcer Test, a 10-minute home test detecting Helicobacter pylori (H. pylori), has been approved for use in the UAE. H. pylori, linked to 80% of gastric cancer cases, is classified as a Class 1 carcinogen by the WHO. Gastric cancer is the fifth most common cancer globally. The test, detecting antibodies to H. pylori, which causes peptic ulcers and dyspepsia, aims to improve early detection and treatment. UAE's 41% population is ...
08-14 12:19
